| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/10/2004 | US6689400 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |
| 02/10/2004 | US6689399 Capsacinoid in conjunction with glucosamine at a high concentration, synergistic; prolonged pain relief effect is achieved without intense burning or stinging sensation usually associated with topical capsaicin |
| 02/10/2004 | US6689398 Triterpene compositions and methods for use thereof |
| 02/10/2004 | US6689393 Glucose concentration can be varied without influencing the concentration of the other components; three individual solutions are combined and administered after heat sterilization; calcium ions, electrolyte salts, and a buffer |
| 02/10/2004 | US6689387 Diindolylmethane, its precursor indole-3- carbinol , and cogener 2-(indol-3-ylmethyl)-3,3'diindolylmethane |
| 02/10/2004 | US6689386 Such as ibuprofen |
| 02/10/2004 | US6689385 Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| 02/10/2004 | US6689384 Stable pergolide mesylate and process for making same |
| 02/10/2004 | US6689383 Significantly improves absorption capability |
| 02/10/2004 | US6689382 Soft shell gelatin capsules containing non-steroidal anti-inflammatories |
| 02/10/2004 | US6689381 Liposome comprising phosphatidylcholine, cholesterol, as well as benzoquinazoline thymidylate synthase inhibitor; improved pharmacokinetics and efficacy as anti-tumor agents compared to free drug |
| 02/10/2004 | US6689379 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 02/10/2004 | US6689373 Implanting a drug delivery device; fentanyl or a fentanyl congener (e.g., sufentanil) |
| 02/10/2004 | US6689372 Microbicidal active substances |
| 02/10/2004 | US6689349 Aging, ultraviolet radiation |
| 02/10/2004 | US6689337 Vitronectin receptor antagonist pharmaceuticals |
| 02/10/2004 | US6689299 Process for producing solid creatine dosage forms and dosage forms obtainable thereby |
| 02/10/2004 | US6689209 Process for preparing low defect density silicon using high growth rates |
| 02/10/2004 | CA2372576C Pharmaceutical composition of fenofibrate presenting a high biodisponibility and its preparation process |
| 02/10/2004 | CA2303291C Fatty acids as a diet supplement |
| 02/10/2004 | CA2291975C Quaternary ammonium compounds |
| 02/10/2004 | CA2274581C Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/10/2004 | CA2274381C Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 |
| 02/10/2004 | CA2268914C Pharmaceutical and cosmetic formulations with antimicrobial activity |
| 02/10/2004 | CA2231026C Novel derivatives of benzenesulfonylamine, process for their preparation and pharmaceutical compositions containing them |
| 02/10/2004 | CA2229597C Oral fast-dissolving compositions for dopamine agonists |
| 02/10/2004 | CA2223551C Benzimidazole compounds |
| 02/10/2004 | CA2214247C Modulators of amyloid aggregation |
| 02/10/2004 | CA2180301C Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
| 02/10/2004 | CA2164951C Lipoxin compounds |
| 02/10/2004 | CA2145631C Two-phase matrix for sustained release drug delivery device |
| 02/10/2004 | CA2134196C Pharmaceutical preparation and process for its manufacture |
| 02/10/2004 | CA2114936C Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones |
| 02/10/2004 | CA2109053C Stabilised hexadecylphosphocholine solutions in glycerol alkyl ethers |
| 02/10/2004 | CA2108903C Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| 02/10/2004 | CA2106474C Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 02/10/2004 | CA2079447C Sustained drug release through topical application of bioadhesive liposomes |
| 02/09/2004 | CA2398828A1 A pharmaceutical composition containing an indolopyrrolocarbazole derivative |
| 02/08/2004 | CA2433114A1 Method of using metaloporphyrins for treatment of arteriosclerotic lesions |
| 02/07/2004 | CA2395931A1 Solid compositions comprising gabapentin having improved stability |
| 02/06/2004 | CA2436890A1 Pharmaceutical preparation with rna as hemostasis cofactor |
| 02/05/2004 | WO2004011680A1 Regulated aptamer therapeutics |
| 02/05/2004 | WO2004011662A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | WO2004011647A1 Modified small interfering rna molecules and methods of use |
| 02/05/2004 | WO2004011632A2 Oligodendrocyte production from multipotent neural stem cells |
| 02/05/2004 | WO2004011626A2 Assays and methods based on microcompetition with a foreign polynucleotide |
| 02/05/2004 | WO2004011625A2 Polymorphisms for predicting disease and treatment outcome |
| 02/05/2004 | WO2004011544A1 Ophtalmic compositions |
| 02/05/2004 | WO2004011481A1 Phosmidosine derivative and process for producing the same |
| 02/05/2004 | WO2004011478A2 Anti-viral 7-deaza d-nucleosides and uses thereof |
| 02/05/2004 | WO2004011476A1 Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer |
| 02/05/2004 | WO2004011470A1 Furoisoquinoline derivative and use thereof |
| 02/05/2004 | WO2004011469A1 Cell differentiation inductor |
| 02/05/2004 | WO2004011468A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |
| 02/05/2004 | WO2004011465A1 Kinase inhibitors |
| 02/05/2004 | WO2004011462A1 Preparation of 1h-imidazo [4,5-c] quinolin-4-amines via novel 1h-imidazo [4,5-c] quinolin-4-cyano and 1h-imidazo [4,5-c] quinolin-4-carboxamide intermediates |
| 02/05/2004 | WO2004011461A1 Isothiazole derivatives useful as anticancer agents |
| 02/05/2004 | WO2004011460A2 Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| 02/05/2004 | WO2004011458A1 Total synthesis of myriaporones |
| 02/05/2004 | WO2004011448A1 Therapeutic compounds for treating dyslipidemic conditions |
| 02/05/2004 | WO2004011444A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011442A1 Pyrimidine derivatives |
| 02/05/2004 | WO2004011441A1 Pyridazinylpiperazine derivatives for treating pain |
| 02/05/2004 | WO2004011440A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredint |
| 02/05/2004 | WO2004011436A1 Quinoline derivatives and their use as mycobacterial inhibitors |
| 02/05/2004 | WO2004011432A1 Organic acid salt of amlodipine |
| 02/05/2004 | WO2004011431A1 Pleuromutilin derivatives as antimicrobbials |
| 02/05/2004 | WO2004011430A1 Sodium channel inhibitor |
| 02/05/2004 | WO2004011425A2 Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives |
| 02/05/2004 | WO2004011423A2 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 02/05/2004 | WO2004011421A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
| 02/05/2004 | WO2004011418A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands |
| 02/05/2004 | WO2004011416A1 CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST |
| 02/05/2004 | WO2004011410A1 Chemical compounds |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004011069A1 Medicament dispenser |
| 02/05/2004 | WO2004011068A1 Medicament dispenser |
| 02/05/2004 | WO2004011067A1 Medicament dispenser |
| 02/05/2004 | WO2004011032A1 External preparation |
| 02/05/2004 | WO2004011031A1 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 02/05/2004 | WO2004011029A2 Pharmaceutical compositions for penis enlargement |
| 02/05/2004 | WO2004011026A1 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 02/05/2004 | WO2004011019A1 Use of a proteasome inhibitor in the treatment of fibrotic diseases |
| 02/05/2004 | WO2004011017A1 Nasal irrigation solutions and methods of using same |
| 02/05/2004 | WO2004011013A1 Psoriasis formulation and method of preparation |
| 02/05/2004 | WO2004011011A1 Oral and dental composition |
| 02/05/2004 | WO2004011010A1 Myocardial perfusion imaging using a2a receptor agonists |
| 02/05/2004 | WO2004011008A1 COMPOSITION CONTAINING AN ANDROGENOUS 11β-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION |
| 02/05/2004 | WO2004011007A1 Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| 02/05/2004 | WO2004011006A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 02/05/2004 | WO2004011005A2 Antimicrobial 2, 4-diamino-pteridine derivatives |
| 02/05/2004 | WO2004011004A1 Formulation of liposomal derivatives of phenylalanine |
| 02/05/2004 | WO2004011003A1 Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve |
| 02/05/2004 | WO2004011002A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 02/05/2004 | WO2004011001A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 02/05/2004 | WO2004011000A1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/05/2004 | WO2004010999A1 Pramipexole once-daily dosage form |
| 02/05/2004 | WO2004010998A1 Sustained-release tablet comprising reboxetine |
| 02/05/2004 | WO2004010997A1 Sustained-release tablet composition of pramipexole |